Prosthetic cardiac valve devices, systems, and methods

Information

  • Patent Grant
  • 12290456
  • Patent Number
    12,290,456
  • Date Filed
    Wednesday, August 21, 2019
    5 years ago
  • Date Issued
    Tuesday, May 6, 2025
    4 days ago
Abstract
A heart valve prosthesis for replacing a diseased native valve in a patient. The valve prosthesis includes a compressible and expandable frame structure and an anchor connected to an outer periphery of the frame structure. The anchor comprises a helical wire having a free end. The valve may further include a valve segment mounted within the frame structure and expanded with the frame structure. The frame structure may be configured for receiving a valve segment.
Description
INCORPORATION BY REFERENCE

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.


FIELD

The present invention relates generally to treatment of heart disease, and more particularly, implantable valve prostheses and treatments for heart valve diseases.


BACKGROUND

Referring to FIGS. 1 and 2, the heart 2 includes four chambers connected by four valves. The upper part of the heart 2 includes the left atrium 25 and right atrium 5. The lower part includes the left ventricle 26 and right ventricle 6. The heart 2 and cardiovascular system operates like a closed circuit. The right side of the heart 2 receives de-oxygenated blood from the body and delivers the blood through the pulmonary artery 7 to the lungs where it becomes re-oxygenated. The oxygenated blood is returned to the left side of the heart 2, referred to as the systemic side, which delivers the oxygenated blood throughout the body.


Blood flow between the heart chambers is regulated by the valves. On the left side of the heart, the mitral valve 4 is located between the left atrium 25 and the left ventricle 26 and the aortic valve 9 is located between the left ventricle 26 and the aorta 1. On the right side of the heart 2, the pulmonary valve 3 is located between the right ventricle 6 and the pulmonary artery 7 and the tricuspid valve 8 is located between the right ventricle 6 and the right atrium 5.


All four of heart valves are passive one-way valves with “leaflets” which open and close in response to differential pressures. For example, in a healthy heart during systole the left ventricle 26 contracts and pushes blood out the aortic valve 9. In turn, the pressure in the left ventricle 26 causes the mitral valve 4 to close thereby preventing blood from going back into the left atrium 25 during systole.


A significant population will acquire valve disease in their lifetime. Congenital heart disease is also a significant problem. Patients with valvular disease have abnormal anatomy and/or function of at least one valve. Congenital valve abnormalities may be tolerated and/or treated palliatively for some years before developing into a life-threatening problem in later years. However, congenital heart disease may present life-threatening risk without notice. Patients may acquire valvular disease from rheumatic fever, heart failure, degenerative leaflet tissue, bacterial infection, and more.


Valvular disease may be caused by several factors as shown in FIGS. 3 to 5. FIG. 3 shows a healthy mitral valve 4. Referring to FIGS. 4 to 5 show a diseased mitral valve 4. The valve 4 in FIG. 4 suffers from insufficiency, also referred to as regurgitation. Such a valve 4 does not fully close and allows blood to flow retrograde. In this case, blood will flow back into the left atrium 25 during systole. FIG. 5 shows a mitral valve 4 with stenosis. Such a valve 4 does not open properly. Some valves 4 can have concomitant insufficiency and stenosis. Other diseases may also be present, such as Barlow's disease, which prevent the valve 4 from functioning properly. These diseases reduce cardiac output and force the heart 2 to work harder, thus increasing the risk of heart failure and chordae failures.


While medications may be used to treat the disease, in many cases the defective valve may need to be repaired or replaced at some point during the patient's lifetime. The native valve can be replaced with a mechanical valve or tissue valve. Mechanical valves have a disc or other member which opens and closes. Although mechanical valves are formed of biocompatible materials, they carry an increased risk of clotting. Thus, patients usually need to take anticoagulants for the remainder of their lives, which presents additional complications. Tissue valves can be formed of human or animal tissue, as well as polymeric materials. Tissue valves, unlike mechanical valves, do not typically require long-term use of anti-coagulants, but because they are formed of a living tissue they are not as widely available nor do they last as long as mechanical valves. Common tissue valves include porcine aortic valves mounted within a stent-like structure.


More recently there has been increased interest in less invasive procedures for implantation of prosthetic valves. One type of percutaneous procedure involves using a catheter to place a prosthetic valve inside of a diseased or injured heart valve.


Existing percutaneous procedures for valve repair still face many challenges. These challenges have limited the adoption of transcatheter procedures to certain patient populations and anatomies. Thus far, transcatheter devices are largely focused on aortic valve procedures and the sickest patient populations who may not be able to tolerate surgery. There is a continuing need for improved transcatheter devices which meet or exceed the performance and safety of surgical valves. Percutaneous valve replacement has also been limited to aortic valve procedures. While a large segment of the population suffers from tricuspid and mitral valve disease, the anatomy and function of these valves present challenges to transcatheter replacement. The aortic valve can be accessed via the femoral artery whereas the mitral valve, for example, typically requires a transseptal approach. The mitral valve anatomy presents more complexities to transcatheter procedures than the aortic valve. For example, as shown in FIG. 4, the mitral valve 4 includes two asymmetrical leaflets 4a, 4b and an irregularly-shaped annulus 4c. The mitral valve 4 also varies far more considerably patient-to-patient than the aortic valve. For these and other reasons, surgical replacement and percutaneous repair thus far are the only widely-available commercial treatments for mitral valve disease.


SUMMARY

It would therefore be desirable to provide a less invasive procedure for repair and replacement of heart valves, including the mitral valve, quicker surgical methods, a variety of different valve assemblies to accommodate the requirements of different patients, and/or prosthetic valves that can accommodate a variety of individual patients. Not necessarily all such aspects or advantages are achieved by any particular embodiment. Thus, various embodiments may be carried out in a manner that achieves or optimizes one advantage or group of advantages taught herein without necessarily achieving other aspects or advantages as may also be taught or suggested herein.


The present disclosure relates to prosthetic cardiac devices, and in some embodiments, prosthetic heart valves such as catheter-based mitral valves.


In a first aspect, a heart valve prosthesis for replacing a diseased native valve in a patient is provided. The heart valve prosthesis includes a compressible and expandable frame structure and an anchor connected to an outer periphery of the frame structure. The anchor comprises a helical wire having a free end. The valve may further include a valve segment within the frame structure. The valve segment may include a biocompatible one-way valve.


In a second aspect, a heart valve prosthesis for replacing a diseased native valve in a heart of a patient is provided. The valve prosthesis comprises a compressible and expandable frame structure, a valve segment disposed within the frame structure, the valve segment comprising a biocompatible one-way valve, and an anchor connected to an outer periphery of the frame structure, wherein the anchor comprises a helical wire having a free end.


In some embodiments, the free end of the helical wire may be configured to guide the helical wire through a commissure of a native valve of a patient.


In some embodiments, the free end may comprise an atraumatic tip. For example, the free end may comprise a ball tip.


In some embodiments, the free end may be configured for piercing tissue.


In some embodiments, the anchor may comprise a first portion comprising the helical wire and another portion.


In some embodiments, the anchor may comprise a plurality of anchors. The plurality of anchors may comprise at least two helical wires having different diameters. Alternatively, or in combination, the plurality of anchors may comprise at least two helical wires having different winding pitches.


In some embodiments, the helical wire may have a generally tubular shape. The free end of the helical wire may extend radially outward from the tubular shape.


In some embodiments, the helical wire may have a generally frustoconical shape. The free end of the helical wire may extend radially outward from the frustoconical shape.


In some embodiments, the frame structure may be configured for expanding within a native valve of a patient.


In some embodiments, the frame structure may have a compressed state sized and dimensioned for percutaneous insertion and an expanded state sized and dimensioned for implantation in a native valve of a patient.


In some embodiments, the frame structure may comprise first and second opposite ends, the first end extending above a native valve and the second end extending below the native valve when the valve prosthesis is positioned across the native valve.


In some embodiments, the frame structure may comprise an expandable stent.


In some embodiments, the frame structure may comprise a generally tubular expanded shape.


In some embodiments, the frame structure may comprise an expanded outer periphery and a compressed outer periphery when subject to an external radial force. The compressed outer periphery may be slightly smaller in diameter than the expanded outer periphery.


In some embodiments, the frame structure may be balloon-expandable.


In some embodiments, the frame structure may be self-expanding.


In some embodiments, at least a portion of the valve segment may be positioned within at least a portion of the frame structure.


In some embodiments, the valve segment may comprise at least one leaflet having an inner layer and an outer layer. The frame structure may be attached to the outer layer at one or more ends of the frame structure.


In some embodiments, the valve segment may comprise a plurality of leaflets. For example, the valve segment may comprise two leaflets.


In some embodiments, the helical wire may comprise a second end, and wherein the second end is attached to the frame structure. The helical wire may be attached to the frame structure only at the location of the second end.


In some embodiments, the anchor and the frame structure may be adapted to be independently and separately expanded.


In another aspect, a method of replacing a diseased native valve of a patient is provided. The method comprises loading a valve prosthesis into a delivery catheter, the valve prosthesis comprising an expandable frame structure carrying a biocompatible valve segment and an anchor attached to an outer periphery of the frame structure, the anchor comprising a wire having a free end; delivering the valve prosthesis to a target location above a native valve; inserting the valve prosthesis through the native valve to a position posterior the native valve; rotating the wire such that the free end wraps around at least a portion of chordae tendineae below the valve; and expanding the frame structure including the valve segment within the native valve.


In some embodiments, the method may further comprise anchoring the valve prosthesis by rotating the wire until the frame structure is positioned within leaflets of the native valve.


In some embodiments, the method may further comprise anchoring the valve prosthesis by rotating the wire until the wire tightens around the chordae tendineae.


In some embodiments, the frame structure may be balloon-expandable. Expanding the frame structure may comprise expanding a balloon within the frame structure.


In some embodiments, the frame structure may be self-expanding. Expanding the frame structure may comprise removing a sheath of the delivery device from the frame structure.


In some embodiments, the wire may be a helical wire.


In some embodiments, inserting the valve prosthesis may comprise guiding the free end of the wire through a commissure of the native valve. In some embodiments, rotating the wire may comprise rotating the wire through the commissure.


In another aspect, a heart valve prosthesis for replacing a diseased native valve in a patient is provided. The valve prosthesis comprises a compressible and expandable frame structure, a valve segment disposed within the frame structure comprising a biocompatible one-way valve, and an anchor connected to the frame structure and disposed radially outward from the frame structure, wherein the anchor comprises a helical member having a free end.


In some embodiments, the second end of the anchor may be connected to the frame structure.


In some embodiments, the helical member may comprise a wire or a flat ribbon.


These and other embodiments are described in further detail in the following description related to the appended drawing figures.





BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the present disclosure are utilized, and the accompanying drawings of which:



FIG. 1 is a schematic of a human heart illustrating the path of blood flow through the heart.



FIG. 2 is a cross-sectional view of a heart looking down through the mitral valve, aortic valve, and aorta.



FIG. 3 is a schematic of a healthy mitral valve.



FIGS. 4 and 5 are schematics of diseased mitral valves.



FIGS. 6 to 10 are several views of a percutaneous valve for replacement of a diseased native valve, in accordance with embodiments.



FIG. 11 is a perspective view of the prosthetic valve leaflet of the valve of FIG. 6, in accordance with embodiments.



FIGS. 12 to 18 are several views of the frame structure of the valve of FIG. 6, in accordance with embodiments.



FIGS. 19 to 26 are several views of the method of implanting the valve of FIG. 6, in accordance with embodiments.



FIGS. 27 to 28 illustrate expanding of the frame structure using a balloon, in accordance with embodiments.



FIG. 29 is a front view of another percutaneous valve similar to the one of FIG. 6, in accordance with embodiments.



FIGS. 30A to 30F are front views of other percutaneous valves similar to the one of FIG. 6, in accordance with embodiments.





The devices and methods of the present disclosure have other features and advantages which will be apparent from or are set forth in more detail in the accompanying drawings, which are incorporated in and form a part of this specification, and the following Detailed Description, which together serve to explain the principles of the present invention.


DETAILED DESCRIPTION

In the following detailed description, reference is made to the accompanying figures, which form a part hereof. In the figures, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, figures, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated herein.


Although certain embodiments and examples are disclosed below, inventive subject matter extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses, and to modifications and equivalents thereof. Thus, the scope of the claims appended hereto is not limited by any of the particular embodiments described below. For example, in any method or process disclosed herein, the acts or operations of the method or process may be performed in any suitable sequence and are not necessarily limited to any particular disclosed sequence. Various operations may be described as multiple discrete operations in turn, in a manner that may be helpful in understanding certain embodiments, however, the order of description should not be construed to imply that these operations are order dependent. Additionally, the structures, systems, and/or devices described herein may be embodied as integrated components or as separate components.


For purposes of comparing various embodiments, certain aspects and advantages of these embodiments are described. Not necessarily all such aspects or advantages are achieved by any particular embodiment. Thus, for example, various embodiments may be carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other aspects or advantages as may also be taught or suggested herein.


The present disclosure is described in relation to deployment of systems, devices, or methods for treatment of a diseased native valve of the heart, for example a mitral valve. However, one of skill in the art will appreciate that this is not intended to be limiting and the devices and methods disclosed herein may be used in other anatomical areas and in other surgical procedures.


For convenience in explanation and accurate definition in the appended claims, the terms “up” or “upper”, “down” or “lower”, “inside” and “outside” are used to describe features of the embodiments with reference to the positions of such features as displayed in the figures.


In many respects the modifications of the various figures resemble those of preceding modifications and the same reference numerals followed by subscripts “a”, “b”, “c”, and “d” designate corresponding parts.


Turning now to the drawings, wherein like components are designated by like reference numerals throughout the various figures, attention is directed to FIGS. 1-5. FIG. 1 shows a human heart 2 and the blood flow pathways through the four chambers of the heart. FIG. 2 is a human heart 2 showing the mitral valve 4, aortic valve 9, and aorta 1. The mitral valve 4 includes two leaflets 4a, 4b. The anterior (aortic) leaflet 4a is adjacent the aorta 1. The posterior (mural) leaflet 4b is remote from the aorta 1. The aortic valve 9 includes three leaflets. In the current view, the heart 2 is in systole with the aortic valve 9 open and the mitral valve 4 closed. Whereas FIG. 1 illustrates a healthy heart 2, FIGS. 2-5 illustrate exemplary mitral valve 4 disease states which may be addressed by the prosthetic valve in accordance with the present disclosure. The prosthetic valve may also be used to treat functional regurgitation such as functional mitral regurgitation (FMR).



FIGS. 6-18 show an exemplary valve prosthesis 10 (also referred to herein as “valve device”) for replacement of a diseased mitral valve in accordance with the present disclosure. The illustrated valve prosthesis 10 comprises a frame structure 12, a valve segment 14, and an anchor 15. FIGS. 6-10 show the valve prosthesis 10 in an expanded, deployed state. FIGS. 12-18 show the frame structure 12 without the valve segment 14. The frame structure 12 is in a collapsed state in FIGS. 12-15 and an expanded state in FIGS. 16-18. The anchor 15 is shown in a deployed state.


The exemplary valve prosthesis 10 will now be described with reference to FIGS. 6-11. In the illustrated embodiment, valve prosthesis 10 is configured for replacement of a native mitral valve. Valve 10 includes a frame structure 12, valve segment 14, and anchor 15. In the illustrated embodiment, the anchor includes a wire 20 formed in a helical or spiral shape around the frame structure.


Exemplary frame structure 12 is configured like a stent. The frame has an expanded state and a collapsed or compressed state. The compressed state is sized and dimensioned for percutaneous insertion and the expanded state sized and dimensioned for implantation in a native valve of a patient. In various embodiments, the frame structure 12 comprises an expanded outer periphery and a compressed outer periphery when subject to an external radial force, the compressed outer periphery being slightly smaller in diameter than the expanded outer periphery. The frame structure 12 is shown in the expanded, deployed state in FIG. 6. The frame structure 12 is shown in the collapsed, delivery state in FIG. 12.


The exemplary frame structure 12 is a scaffold in a diamond pattern formed from a shape memory material (e.g. NiTi). One of ordinary skill in the art will appreciate from the description herein that many other structures, materials, and configurations may be employed for the frame structure 12. For example, the frame structure 12 may be formed of a polymer of sufficient elasticity. The frame structure 12 may be formed of a combination of a metal and polymer, such as a metal (e.g. shape memory material) covered in polymer. The frame structure 12 may include a variety of patterns besides diamond shapes.


Valve prosthesis 10 includes a valve segment 14 within the frame structure 12. The exemplary valve segment 14 is expandable and collapsible. In the illustrated embodiment, the valve segment 14 is affixed within the frame structure 12 and expands and collapses with the frame structure 12. Valve segment is used somewhat interchangeably with prosthetic valve leaflet and generally refers to the prosthetic leaflets and frame. As used herein, “prosthetic valve” may refer to all manner of prosthetic and artificial replacement valves including tissue (biological) valves, tissue-engineered valves, polymer valves (e.g. biodegradable polymer valves), and even certain mechanical valves.


In the illustrated embodiment, frame structure 12 is a closed frame such that blood flow is forced through valve segment 14 therein. One or more skirts and/or seals may help force blood through valve segment 14.


Valve segment 14 can be configured as would be understood by one of skill from the description herein. The valve segment 14 can be similar to existing transcatheter valves. The valve segment 14 can be similar to existing surgical tissue valves, and mechanical valves. In various embodiments, the valve segment 14 includes leaflets 16 formed of multi-layered materials for preferential function. At least one leaflet 16 may have an inner layer and an outer layer. In various embodiments, the leaflet 16 is connected to a valve structure which in turn is connected to the frame structure 12. The valve structure may be connected to the frame structure 12 before or after the frame structure 12 has been deployed adjacent a native valve. In various embodiments, the leaflet 16 is attached to the frame structure 12 directly. The leaflet 16 may have an inner layer and an outer layer, with the outer layer attached to the frame structure 12. The leaflet 16 may be attached to an end of the frame structure 12. Alternatively, or in combination, the leaflet 16 may be attached to an intermediate portion of the frame structure 12. In various embodiments, the valve segment 14 includes a plurality of leaflets 16, such as two, three, or more leaflets. In the illustrated embodiment, the valve segment 14 includes three leaflets 16 which are attached to frame structure 12. An exemplary leaflet 16 is shown in FIG. 11. The leaflet 16 is concave to permit flow in one direction. In particular, flow in one direction causes the leaflet(s) 16 to deflect open and flow in the opposite direction causes the leaflet(s) 16 to close.


Turning back to FIGS. 6-18, and more particularly FIGS. 12-18, an exemplary anchor 15 comprises a helical member, such as wire 20, having a free end 22. The other end of the wire 20 is attached to a top end of frame structure 12. In the illustrated embodiment, one end of the wire 20 is fixed to a strut of the frame structure 12. This end can be attached by suitable means as would be understood by one of skill in the art from the description herein including, but not limited to, a weld, an adhesive, and a mechanical fastener. In various embodiments, the helical wire 20 is attached to the frame structure only at the location of the second end.


Although referred to as an anchor, one will appreciate that anchor 15 does not require performing an anchor function in the traditional sense. As will be described in more detail below, the anchor guides valve prosthesis 10 into a desired position within a native valve. The anchor 15 may also mitigate against undesired entanglement and disturbances to the chordae tendineae and valve leaflets of the mitral valve.


Wire 20 is formed of a material having sufficient rigidity to hold a predetermined shape. In the exemplary embodiment, the wire 20 is formed of a shape memory material (e.g. NiTi). It may be desirable for at least an end portion to be relatively rigid such that it can exert a force to move chordae tendineae, while still retaining flexibility to be collapsed within a catheter. In various embodiments, the end portion (including free end 22) only needs sufficient rigidity to hold its shape and will deform under a load. For example, the end portion may be configured with similar rigidity to a guidewire, or slightly stiffer.


In various embodiments, the anchor 15 comprises a helical member. The helical member may comprise a helical wire or flat ribbon. The helical member may comprise a three-dimensional surface as described herein.


In various embodiments, the anchor 15 may comprise a first portion comprising the helical wire 20 and another portion. Alternatively or in combination, the anchor 15 may comprise a plurality of helical wires 20. For example, the anchor 15 may comprise at least two helical wires 20 having the same or different diameters. Alternatively or in combination, the anchor 15 may comprise at least two helical wires 20 having the same or different winding pitches.


In various embodiments, the anchor 15 may comprise a plurality of anchors, for example a plurality of helical wires 20 as described herein.


In the illustrated embodiment, valve prosthesis 10 is configured for replacing a mitral valve and free end 22 is configured for insertion through a commissure. FIG. 1 is a schematic of a human heart 2 having a mitral valve 4. FIGS. 2 and 4 show an exemplary mitral valve 4. As can be seen in the figures, several commissure points (anterolateral commissure 4d and posteromedial commissure 4e) are presented at the ends of the valve leaflets 4a, 4b.


With continued reference to FIGS. 6-18, the exemplary free end 22 is sized and dimensioned for insertion through one of the commissures. In the various embodiments, the free end 22 is configured to be atraumatic to avoid risk of injury to the valve tissue and leaflets. The free end 22 may be in the form of a blunt end, a ball tip, a curved tip (e.g., J-tip or pigtail), and other atraumatic shapes. In various embodiments, the free end 22 is configured with a sharp end to pierce tissue.


In various embodiments, wire 20 has varying stiffness along its length. The wire 20 may have two or more segments of differing stiffness and/or the stiffness may transition over its length. In various embodiments, wire 20 is attached to frame 12 at multiple points such that free end 22 is relatively flexible and the wire 20 is more rigid along portions where it is attached to the frame structure 12.


In various embodiments, free end 22 extends radially outward from frame structure 12, and in particular the remainder of wire 20. As will be described below, the free end 22 is configured to encircle a larger radius than the main coils of the wire 20. For example, when the main coils of wire 20 have a generally tubular shape, the free end 22 may extend radially outward from the tubular shape. When the main coils of wire 20 have a generally helical shape, the free end 22 may extend radially outward from the helical shape. When the main coils of wire 20 have a generally frustoconical shape, the free end 22 may extend radially outward from the frustoconical shape. The larger diameter facilitates capturing of the valve leaflets and/or chordae tendineae within the sweep of the free end 22 during rotation as will be described in more detail below.


The method of implanting valve prosthesis 10 in accordance with the present disclosure will now be described with reference to FIGS. 19-28. Although shown and described with respect to a mitral valve, one will understand that the principles described herein may be applied equally to other atrioventricular valves. Aspects of the procedure, delivery tool, and implanted valve prosthesis are similar to those described in U.S. Pat. Nos. 9,034,032; 9,005,273; 8,323,336; 8,075,615; 7,621,948; and 7,175,656 and U.S. Pub. No. 2011/0288637, which are incorporated herein for all purposes in their entirety.


Prior to implantation, valve prosthesis 10 is collapsed and loaded into a delivery device 30, for example, a delivery catheter. The valve system is optionally primed before or after loading into the delivery catheter 30. FIG. 19 shows a cross-sectional side view of a heart 2 with a transseptal puncture 27 in the atrial septum thereof. The leaflets 42 of valve 4 do not fully prolapse and the patient is experiencing regurgitation.


Next, the delivery catheter 30 is inserted through an introducer into a vessel. The delivery catheter 30 can be guided over a guidewire to a target location using the Seldinger technique. In the illustrated embodiment, the delivery catheter 30 is guided to the left atrium 25 through a transseptal puncture 27 in conventional fashion as shown in FIG. 20.


Turning to FIGS. 21-22, at this point, the end of the delivery catheter 30 is pointed towards the mitral valve 4. Valve prosthesis 10 is then pushed out of the distal end of delivery catheter 30. The delivery device 30 may comprise an outer catheter 50 and an inner catheter or shaft 52. In some embodiments, once the delivery device 30 is in position, the delivery tube 52 extends out of the outer catheter 50 to move valve device 10 distally towards the native valve 4. As the valve prosthesis 10 comes out from the delivery catheter 30, an anchor 15, such as wire 20, is deployed (e.g., from a straightened shape within the delivery device 30) to its pre-formed deployed shape and wraps around frame 12, which remains in its collapsed state as shown in FIG. 22. The valve prosthesis 10 is then aligned with the target native valve 4 so the axis of the prosthetic valve 10 is aligned with a central axis of the native valve 4.


Turning to FIGS. 23-24, valve 10 is anchored to the native valve 4 using exemplary helical wire 20. The valve prosthesis 10—frame 12, wire 20, and valve segment 14—are slowly rotated into the native mitral valve 4. In the illustrated embodiment, a torquer is provided in the delivery catheter 30 for rotating valve 10. Free end 22 of wire 20 is rotated through a commissure and extends below the native valve 4 annulus. The valve prosthesis 4 is further rotated so the free end 22 captures the chordae tendineae (also referred to as “papillary muscles”) 40 and/or native valve leaflets 42. As the wire 20 is continually rotated, the chordae tendineae 40 are gathered and pulled radially inward. Free end 22 has a larger radius than the main body of the helical coil in order to facilitate capture of the chordae tendineae 40 during rotation of the valve prosthesis 10. Frame structure 12 also moves into the native valve 4 as the wire 20 is rotated. Valve prosthesis 10 is in the correct position when the chordae tendineae 40 have been captured to a sufficient degree and/or frame structure 12 is in the desired location in the native valve 40. Insertion of the device through the native valve may be facilitated by the natural opening and closing of the native valve during the cardiac cycle. In the illustrated embodiment, the chordae tendineae 40 are pulled inwardly into a bunches (best seen in FIG. 25). The native valve leaflets 42 are also in communication with the helical coil 20. At this stage valve device 10 is rigidly anchored adjacent the native valve 40 annulus.


If the clinician desires to remove or reposition the valve, the helical wire 20 can be counter-rotated to back out the device 10 from the native valve 4. The implant rotation procedure can then be repeated.


Frame structure 12 is expanded once valve 10 is in the desired location as shown in FIG. 25. The frame structure 12 may comprise a first and second opposite ends, the first end extending above a native valve and the second end extending below the native valve when the frame structure 12 is anchored to the native valve 4. In the illustrated embodiment, the frame structure 12 is expanded with a balloon 48 as shown in FIGS. 27-28. In various embodiments, the frame structure 12 is self-expanding. The self-expanding exemplary frame structure 12 is formed of a shape memory material or any material having superelastic properties. The self-expanding frame structure 12 is configured and expands in a similar manner to a self-expanding stent or scaffold. Expanding the frame structure 12 comprises removing a sheath (for example, outer sheath 50) of the delivery device 30 from the frame structure 12.


Once the frame structure 12 is expanded the entire valve assembly 10 is released from the delivery catheter 30 and the delivery catheter 30 is removed as shown in FIG. 26. In some embodiments, expansion of the frame structure 12 may occur simultaneously with release of the frame structure 12 from the delivery catheter 30.


In the illustrated embodiment, the valve structure 14 and frame structure 12 are deployed together. One of ordinary skill in the art will appreciate, however, that the frame structure 12 can be deployed first and then receive the prosthetic valve segment 14.


In various embodiments, valve prosthesis 10 does not include a valve segment 14. Instead, the frame structure 12 and anchor 15 are positioned within the native valve 4. The frame structure 12 is configured to receive a valve segment 14 delivered separately. In certain embodiments, the frame structure 12 can be configured to receive one of several valve sizes and types. In this manner, a clinician can choose the proper valve for the individual patient.


In the illustrated embodiment, the helical wire 20 of anchor 15 guides the valve system 10 along a desired axis into position adjacent the native valve 4. The wire 20 also provides an initial anchoring. The valve prosthesis 10 is finally anchored when the frame structure 12 is expanded within the native valve 4. The frame structure 12 dilates the valve leaflets 14 and the compressive force fixes the valve prosthesis 10 into position. Thereafter tissue ingrowth ensures the valve prosthesis 10 remains seated and does not migrate.


The valve device in accordance with the present disclosure provides several advantages over conventional valve systems. Embodiments described herein provide an easy-to-use, repositionable device. Unlike conventional valve systems, the valve prosthesis described herein reduces the risk of injuring or tearing chordae. Typical mitral valve replacement systems involve implanting a prosthetic annulus or ring around the valve. The ring increases the circumference of the valve and risks occluding the entry to the aortic valve. The valve device described herein overcomes these and other problems.



FIG. 29 illustrates another embodiment in accordance with the present disclosure. A valve prosthesis 10′ includes a helical wire 20′ and frame structure 12′. Valve structure 10′ is similar to valve 10 except that valve segment 14′ is fixed within a separate end of frame structure 12′. Wire 20′ is wrapped around a lower portion of the frame structure 12 having a smaller diameter than the upper portion of the frame structure 12 to which the valve segment 14′ is fixed.



FIGS. 30A to 30F illustrate several other embodiments in accordance with the present disclosure. Each of valves 10a to 10f includes a helical wire and frame. Each can optionally include a valve segment within the frame.



FIG. 30A shows a valve prosthesis 10a which is similar to valve prosthesis 10 except that free end 22a includes an atraumatic ball tip. Also, wire 20a has a tubular shape at one end and a frustoconical shape at another end. Frame structure 12a is substantially similar to frame structure 12.



FIG. 30B shows a valve prosthesis 10b which is similar to valve prosthesis 10 except that free end 22 has a pigtail tip. Also, wire 20b is attached to an intermediate portion of frame structure 12b instead of an end of the frame structure 12b. Frame structure 12b is substantially similar to frame structure 12.



FIG. 30C shows a valve prosthesis 10c which is similar to valve prosthesis 10 except that frame structure 12c is a tubular structure instead of a scaffold or stent-like structure. The frame structure 12c can be formed of expandable materials such as polyurethane or polycarbonate urethane. The wire 20c is substantially similar to wire 20. The free end 22c is substantially similar to free end 22.



FIG. 30D shows a valve prosthesis 10d which is similar to valve prosthesis 10 except that the anchor 15 is formed of a three-dimensional surface 20d instead of a wire 20. Three-dimensional surface 20d comprises a free end 22d, which may be substantially similar to any of the free ends described herein. Frame structure 12d is substantially similar to frame structure 12.



FIG. 30E shows a valve prosthesis 10e which is similar to valve prosthesis 10 except that frame structure 12e has a conical shape instead of a tubular shape. One will appreciate from the description herein that the frame structure 12 may take a variety of shapes in accordance with the present disclosure. The wire 20e is substantially similar to wire 20. The free end 22e is substantially similar to free end 22.



FIG. 30F shows a valve prosthesis 10f which is similar to valve prosthesis 10 except that the valve device 10f includes a plurality of wires 20f and 20f′. The use of a plurality of wires 20f and 20f′ provides increased anchoring security. Because it may be difficult to insert both free ends 22f and 22f′, one or both free ends 22f and 22f′ may include a sharp point for piercing tissue. In this manner, the sharp end can pierce the valve annulus or leaflets. Barbs or other mechanisms may be employed to increase anchoring of the wire. For example, one or both of the wires 20f and 20f′ may include a braided surface or barbs to prevent axial dislocation once it is screwed into place.


When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.


Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.


Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.


Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.


Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.


When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.


Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.


Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.


Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.


Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.


As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.


The foregoing descriptions of specific embodiments of the present invention have been presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed, and obviously many modifications, changes, substitutions, alternatives, and variations are possible in light of the above teaching. The embodiments were chosen and described to best explain the principles of the invention and its practical application, to thereby enable others skilled in the art to best utilize the invention and various embodiments with various modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the Claims appended hereto and their equivalents.

Claims
  • 1. A heart valve prosthesis for replacing a diseased native valve in a heart of a patient, the valve prosthesis comprising: a compressible and expandable frame structure having a frame axis;a valve segment disposed within the frame structure, the valve segment comprising a biocompatible one-way valve; anda compressible and expandable anchor permanently attached to and configured to encircle an outer periphery of the frame structure, wherein the anchor comprises a spiral wire and a free end, the free end having a larger radius of curvature than the spiral wire;wherein the heart valve prosthesis has an anchoring configuration in which the anchor is in an expanded state, the frame structure is in a collapsed state, and the frame axis is centrally located within the spiral wire;wherein when heart valve prosthesis is in the anchoring configuration, rotation of the spiral wire is configured to guide the frame structure into the native valve.
  • 2. The valve prosthesis of claim 1, wherein the free end is configured to guide the spiral wire through a commissure of a native valve of a patient.
  • 3. The valve prosthesis of claim 1, wherein the free end comprises an atraumatic tip.
  • 4. The valve prosthesis of claim 3, wherein the free end comprises a ball tip.
  • 5. The valve prosthesis of claim 1, wherein the free end is configured for piercing tissue.
  • 6. The valve prosthesis of claim 1, wherein the frame structure is configured for expanding within a native valve of a patient.
  • 7. The valve prosthesis of claim 1, wherein the frame structure has a compressed state sized and dimensioned for percutaneous insertion and an expanded state sized and dimensioned for implantation in a native valve of a patient.
  • 8. The valve prosthesis of claim 1, wherein the frame structure comprises first and second opposite ends, the first end configured to extend above a native valve and the second end configured to extend below the native valve when the valve prosthesis is positioned across the native valve.
  • 9. The valve prosthesis of claim 1, wherein the frame structure comprises an expandable stent.
  • 10. The valve prosthesis of claim 1, wherein the frame structure comprises a generally tubular expanded shape.
  • 11. The valve prosthesis of claim 1, wherein the frame structure comprises an expanded outer periphery and a compressed outer periphery when subject to an external radial force, wherein the compressed outer periphery is smaller in diameter than the expanded outer periphery.
  • 12. The valve prosthesis of claim 1, wherein the frame structure is self-expanding.
  • 13. The valve prosthesis of claim 1, wherein the valve segment comprises at least one leaflet having an inner layer and an outer layer, and wherein the frame structure is attached to the outer layer at one or more ends of the frame structure.
  • 14. The valve prosthesis of claim 1, wherein the valve segment comprises a plurality of leaflets.
  • 15. The valve prosthesis of claim 14, wherein the valve segment comprises two leaflets.
  • 16. The valve prosthesis of claim 1, wherein the anchor and the frame structure are adapted to be independently and separately expanded.
  • 17. The valve prosthesis of claim 1, wherein the spiral wire is fixedly connected to the frame structure only at one end of the spiral wire.
  • 18. The valve prosthesis of claim 1, wherein the free end is configured to capture chordae tendineae of the native valve when the anchor is rotated within the heart in the anchoring configuration.
  • 19. The valve prosthesis of claim 1, wherein in the anchoring configuration, the frame axis is aligned with a central axis of the anchor.
  • 20. The valve prosthesis of claim 1, wherein the anchor is configured to concentrically encircle the outer periphery of the frame structure.
CROSS-REFERENCE

This application claims the benefit of U.S. Provisional Patent Application No. 62/720,853, filed on Aug. 21, 2018, entitled Prosthetic Cardiac Valve Devices, Systems, and Methods; which is incorporated herein for all purposes in their entirety.

US Referenced Citations (627)
Number Name Date Kind
4725274 Lane et al. Feb 1988 A
5002563 Pyka et al. Mar 1991 A
5327905 Avitall Jul 1994 A
5356424 Buzerak et al. Oct 1994 A
5370685 Stevens Dec 1994 A
5582616 Bolduc et al. Dec 1996 A
5716397 Myers Feb 1998 A
5755601 Jones May 1998 A
5779669 Haissaguerre et al. Jul 1998 A
5873835 Hastings et al. Feb 1999 A
5944690 Falwell et al. Aug 1999 A
5997526 Giba et al. Dec 1999 A
6048339 Zirps et al. Apr 2000 A
6053873 Govari et al. Apr 2000 A
6254550 McNamara et al. Jul 2001 B1
6419695 Gabbay Jul 2002 B1
6419696 Ortiz et al. Jul 2002 B1
6530952 Vesely Mar 2003 B2
6533783 Töllner Mar 2003 B1
6641553 Chee et al. Nov 2003 B1
6752813 Goldfarb et al. Jun 2004 B2
6869444 Gabbay Mar 2005 B2
6908478 Alferness et al. Jun 2005 B2
6964684 Ortiz et al. Nov 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
7077861 Spence Jul 2006 B2
7101395 Tremulis et al. Sep 2006 B2
7125421 Tremulis et al. Oct 2006 B2
7160322 Gabbay Jan 2007 B2
7175656 Khairkhahan Feb 2007 B2
7201771 Lane Apr 2007 B2
7226467 Lucatero et al. Jun 2007 B2
7381219 Salahieh et al. Jan 2008 B2
7329279 Haug et al. Feb 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7470285 Nugent et al. Dec 2008 B2
7527647 Spence May 2009 B2
7534261 Friedman May 2009 B2
7563267 Goldfarb et al. Jul 2009 B2
7594903 Webler et al. Sep 2009 B2
7604646 Goldfarb et al. Oct 2009 B2
7608091 Goldfarb et al. Oct 2009 B2
7618449 Tremulis et al. Nov 2009 B2
7621948 Herrmann et al. Nov 2009 B2
7666204 Thornton et al. Feb 2010 B2
7704269 St. Goar et al. Apr 2010 B2
7731705 Wardle Jun 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7749266 Forster et al. Jul 2010 B2
7780725 Haug et al. Aug 2010 B2
7799069 Bailey et al. Sep 2010 B2
7811296 Goldfarb et al. Oct 2010 B2
7824442 Salahieh et al. Nov 2010 B2
7824443 Salahieh et al. Nov 2010 B2
7846203 Cribier Dec 2010 B2
7942927 Kaye et al. May 2011 B2
7947075 Goetz et al. May 2011 B2
7951195 Antonsson et al. May 2011 B2
7959666 Salahieh et al. Jun 2011 B2
7988724 Salahieh et al. Aug 2011 B2
8021421 Fogarty et al. Sep 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8052750 Tuval et al. Nov 2011 B2
8062355 Figulla et al. Nov 2011 B2
8070800 Lock et al. Dec 2011 B2
8075615 Eberhardt et al. Dec 2011 B2
8096985 Legaspi et al. Jan 2012 B2
8147541 Forster et al. Apr 2012 B2
8147542 Maisano et al. Apr 2012 B2
8182528 Salahieh et al. May 2012 B2
8216256 Raschdorf et al. Jul 2012 B2
8236049 Rowe et al. Aug 2012 B2
8241351 Cabiri Aug 2012 B2
8251977 Partlett Aug 2012 B2
8252050 Maisano et al. Aug 2012 B2
8287584 Salahieh et al. Oct 2012 B2
8313526 Hoffman et al. Nov 2012 B2
8323241 Salahieh et al. Dec 2012 B2
8323336 Hill et al. Dec 2012 B2
8328868 Paul et al. Dec 2012 B2
8343213 Salahieh et al. Jan 2013 B2
8348995 Tuval et al. Jan 2013 B2
8348996 Tuval et al. Jan 2013 B2
8366767 Zhang Feb 2013 B2
8403981 Forster et al. Mar 2013 B2
8403983 Quadri et al. Mar 2013 B2
8414643 Tuval et al. Apr 2013 B2
8414644 Quadri et al. Apr 2013 B2
8414645 Dwork et al. Apr 2013 B2
8425593 Braido et al. Apr 2013 B2
8449599 Chau et al. May 2013 B2
8454686 Alkhatib Jun 2013 B2
8465541 Dwork Jun 2013 B2
8500800 Maisano et al. Aug 2013 B2
8512401 Murray et al. Aug 2013 B2
8523881 Cabiri et al. Sep 2013 B2
8545553 Zipory et al. Oct 2013 B2
8556963 Tremulis et al. Oct 2013 B2
8562645 Stone et al. Oct 2013 B2
8562673 Yeung et al. Oct 2013 B2
8579962 Salahieh et al. Nov 2013 B2
8603157 Seguin et al. Dec 2013 B2
8603160 Salahieh et al. Dec 2013 B2
8623075 Murray et al. Jan 2014 B2
8628570 Seguin Jan 2014 B2
8641727 Starksen et al. Feb 2014 B2
8652202 Alon et al. Feb 2014 B2
8652203 Quadri et al. Feb 2014 B2
8657872 Seguin Feb 2014 B2
8685086 Navia Apr 2014 B2
8696693 Najafi et al. Apr 2014 B2
8715300 Najafi et al. May 2014 B2
8715342 Zipory et al. May 2014 B2
8740976 Tran et al. Jun 2014 B2
8784479 Antonsson et al. Jul 2014 B2
8790367 Nguyen et al. Jul 2014 B2
8808368 Maisano et al. Aug 2014 B2
8828078 Salahieh et al. Sep 2014 B2
8834564 Tuval et al. Sep 2014 B2
8840663 Salahieh et al. Sep 2014 B2
8840664 Karapetian et al. Sep 2014 B2
8845588 Bruszewski Sep 2014 B2
8852271 Murray et al. Oct 2014 B2
8876893 Dwork et al. Nov 2014 B2
8876894 Tuval et al. Nov 2014 B2
8876895 Tuval et al. Nov 2014 B2
8900294 Paniagua et al. Dec 2014 B2
8911494 Hammer et al. Dec 2014 B2
8920369 Salahieh et al. Dec 2014 B2
8926690 Kowalsky Jan 2015 B2
8926696 Cabiri et al. Jan 2015 B2
8926697 Gross et al. Jan 2015 B2
8940002 Goertzen Jan 2015 B2
8940044 Hammer et al. Jan 2015 B2
8951299 Paul et al. Feb 2015 B2
8986371 Quill et al. Mar 2015 B2
8998980 Shipley et al. Apr 2015 B2
9005273 Salahieh et al. Apr 2015 B2
9011515 Schweich et al. Apr 2015 B2
9011523 Seguin Apr 2015 B2
9011530 Reich et al. Apr 2015 B2
9017408 Siegal et al. Apr 2015 B2
9023100 Quadri et al. May 2015 B2
9034032 McLean et al. May 2015 B2
9039757 McLean et al. May 2015 B2
9056009 Keränen Jun 2015 B2
9061120 Osypka et al. Jun 2015 B2
9078747 Conklin Jul 2015 B2
9095431 Yu et al. Aug 2015 B2
9119719 Zipory et al. Sep 2015 B2
9125739 Paniagua et al. Sep 2015 B2
9125740 Morriss et al. Sep 2015 B2
9155619 Líu et al. Oct 2015 B2
9168129 Valdez et al. Oct 2015 B2
9168131 Yohanan et al. Oct 2015 B2
9173713 Hart et al. Nov 2015 B2
9173737 Hill et al. Nov 2015 B2
9180006 Keränen Nov 2015 B2
9226823 Dwork Jan 2016 B2
9232995 Kovalsky et al. Jan 2016 B2
9277994 Miller et al. Mar 2016 B2
9289297 Wilson et al. Mar 2016 B2
9295547 Costello et al. Mar 2016 B2
9301756 Wardle Apr 2016 B2
9301836 Buchbinder et al. Apr 2016 B2
9320597 Savage et al. Apr 2016 B2
9343224 Zilbershlag May 2016 B2
9358110 Paul et al. Jun 2016 B2
9414915 Lombardi et al. Aug 2016 B2
9427315 Schweich et al. Aug 2016 B2
9439757 Wallace et al. Sep 2016 B2
9468525 Kovalsky Oct 2016 B2
9474606 Zipory et al. Oct 2016 B2
9474840 Siess Oct 2016 B2
9480559 Vidlund et al. Nov 2016 B2
9492273 Wallace et al. Nov 2016 B2
9526487 Rahmani Dec 2016 B2
9526609 Salahieh et al. Dec 2016 B2
9532868 Braido Jan 2017 B2
9532870 Cooper et al. Jan 2017 B2
9561102 Rust et al. Feb 2017 B2
9572662 Morriss et al. Feb 2017 B2
9579196 Morriss et al. Feb 2017 B2
9579198 Deem et al. Feb 2017 B2
9585751 Morriss et al. Mar 2017 B2
9636224 Zipory et al. May 2017 B2
9636481 Campbell et al. May 2017 B2
9662202 Quill et al. May 2017 B2
9662206 Börtlein et al. May 2017 B2
9662209 Gross et al. May 2017 B2
9675454 Vidlund et al. Jun 2017 B2
9681952 Hacohen et al. Jun 2017 B2
9687343 Börtlein et al. Jun 2017 B2
9724192 Sheps et al. Aug 2017 B2
9730790 Quadri et al. Aug 2017 B2
9730793 Reich et al. Aug 2017 B2
9744031 Girard et al. Aug 2017 B2
9744038 Dahlgren et al. Aug 2017 B2
9750605 Ganesan et al. Sep 2017 B2
9763779 Börtlein et al. Sep 2017 B2
9763780 Morriss et al. Sep 2017 B2
9814611 Cartledge et al. Nov 2017 B2
9827090 Hill et al. Nov 2017 B2
9861480 Zakai et al. Jan 2018 B2
9867700 Bakis et al. Jan 2018 B2
9867702 Keränen et al. Jan 2018 B2
9877833 Bishop et al. Jan 2018 B1
9883941 Hastings et al. Feb 2018 B2
9889003 Börtlein et al. Feb 2018 B2
9895221 Vidlund Feb 2018 B2
9895222 Zeng et al. Feb 2018 B2
9901444 Valdez et al. Feb 2018 B2
9918840 Reich et al. Mar 2018 B2
D815744 Ratz et al. Apr 2018 S
9949825 Braido et al. Apr 2018 B2
9949828 Sheps et al. Apr 2018 B2
9950142 Eversull et al. Apr 2018 B2
9968452 Sheps et al. May 2018 B2
9974647 Ganesan et al. May 2018 B2
9974650 Nguyen-Thien-Nhon et al. May 2018 B2
9999502 Nasr et al. Jun 2018 B2
9999504 Czyscon et al. Jun 2018 B2
10004599 Rabito et al. Jun 2018 B2
10016271 Morriss et al. Jul 2018 B2
10016272 Spence et al. Jul 2018 B2
10028827 Morriss et al. Jul 2018 B2
10028832 Quill et al. Jul 2018 B2
10029037 Muller et al. Jul 2018 B2
10034747 Harewood Jul 2018 B2
10034749 Spence Jul 2018 B2
10034750 Morriss et al. Jul 2018 B2
10039637 Maimon et al. Aug 2018 B2
10045846 Bonyuet et al. Aug 2018 B2
10052198 Chau Aug 2018 B2
10052199 Spence et al. Aug 2018 B2
10058318 Tegzes Aug 2018 B2
10058321 Sampson et al. Aug 2018 B2
10064719 Börtlein et al. Sep 2018 B2
10070954 Braido et al. Sep 2018 B2
10092400 Jimenez et al. Oct 2018 B2
10098734 Hoang Oct 2018 B2
10105217 Keränen Oct 2018 B2
10105224 Buchbinder et al. Oct 2018 B2
10130464 Meiri et al. Nov 2018 B2
10130471 Keränen et al. Nov 2018 B2
10143552 Wallace et al. Dec 2018 B2
10149759 Naor Dec 2018 B2
10172708 Anderson Jan 2019 B2
10172711 Keränen Jan 2019 B2
10179042 Braido et al. Jan 2019 B2
10195021 Keränen et al. Feb 2019 B2
10195025 Levi et al. Feb 2019 B2
10195027 Nasr Feb 2019 B2
10195028 Hosmer et al. Feb 2019 B2
10195029 Keränen Feb 2019 B2
10201418 Biadillah et al. Feb 2019 B2
10206775 Kovalsky et al. Feb 2019 B2
10213307 Dwork et al. Feb 2019 B2
10226330 Spence et al. Mar 2019 B2
10226334 Rowe et al. Mar 2019 B2
10226339 Spence Mar 2019 B2
10238489 Conklin Mar 2019 B2
10251749 Zerkowski et al. Apr 2019 B2
10258464 Delaloye et al. Apr 2019 B2
10258468 Deem et al. Apr 2019 B2
10265169 Desrosiers et al. Apr 2019 B2
10271950 Neustadter Apr 2019 B2
10299917 Morriss et al. May 2019 B2
10299921 Dale et al. May 2019 B2
10321988 Gorman et al. Jun 2019 B2
10321989 Keränen Jun 2019 B2
10327743 St. Goar et al. Jun 2019 B2
10327766 Zerkowski et al. Jun 2019 B2
10335277 Crisostomo et al. Jul 2019 B2
10338724 Zhao Jul 2019 B2
10350066 Cooper et al. Jul 2019 B2
10357351 Cooper et al. Jul 2019 B2
10357634 Simmons et al. Jul 2019 B2
10363130 Armer et al. Jul 2019 B2
10363131 Eidenschink et al. Jul 2019 B2
10368986 Gosal et al. Aug 2019 B2
10368990 Noe et al. Aug 2019 B2
10376266 Herman et al. Aug 2019 B2
10376360 Bruchman et al. Aug 2019 B2
10376363 Quadri et al. Aug 2019 B2
10398547 Li et al. Sep 2019 B2
10426608 Salahieh et al. Oct 2019 B2
10433961 McLean Oct 2019 B2
10463479 Manash Nov 2019 B2
10470881 Noe et al. Nov 2019 B2
10478291 Nguyen et al. Nov 2019 B2
10500048 Khairkhahan et al. Dec 2019 B2
10507104 Zhang et al. Dec 2019 B2
10512541 Zerkowski et al. Dec 2019 B2
10524901 Quadri et al. Jan 2020 B2
10548729 Zipory et al. Feb 2020 B2
10568737 Noe et al. Feb 2020 B2
10575951 Johnson et al. Mar 2020 B2
10603165 Maimon et al. Mar 2020 B2
10639154 Seguin May 2020 B2
10653524 Khairkhahan et al. May 2020 B2
10660753 Pham et al. May 2020 B2
10687938 Patel et al. Jun 2020 B2
10695160 Lashinski et al. Jun 2020 B2
10702386 Khairkhahan et al. Jul 2020 B2
10709552 Backus et al. Jul 2020 B2
10716662 Delaloye et al. Jul 2020 B2
10722351 Griffin Jul 2020 B2
10722352 Spence Jul 2020 B2
10722353 Levi Jul 2020 B2
10729542 Howard et al. Aug 2020 B2
10743991 Brown Aug 2020 B2
10751180 Schewel Aug 2020 B2
10751184 Reich et al. Aug 2020 B2
10765514 Iflah et al. Sep 2020 B2
10813749 Nguyen et al. Oct 2020 B2
10828153 Noe et al. Nov 2020 B2
10856970 Tuval et al. Dec 2020 B2
10869755 Granada et al. Dec 2020 B2
10888420 Bateman et al. Jan 2021 B2
10912644 Argento Feb 2021 B2
10973629 Levi et al. Apr 2021 B2
10973630 Tonianni et al. Apr 2021 B2
11007057 Pham et al. May 2021 B2
11020221 Arcaro et al. Jun 2021 B2
11039922 Konno Jun 2021 B2
11103345 Levi et al. Aug 2021 B2
11147670 Hayoz et al. Oct 2021 B2
11234818 Zerkowski et al. Feb 2022 B2
11547563 Keränen et al. Jan 2023 B2
11672657 Argento Jun 2023 B2
11833034 Argento Dec 2023 B2
11986389 Argento May 2024 B2
12053371 Adamek-Bowers Aug 2024 B2
20020173841 Ortiz et al. Nov 2002 A1
20030114913 Spenser et al. Jun 2003 A1
20030233142 Morales et al. Dec 2003 A1
20040039442 St. Goar et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050165344 Dobak, III Jul 2005 A1
20050240202 Shennib et al. Oct 2005 A1
20050277839 Alderman et al. Dec 2005 A1
20060009841 McGuckin, Jr. et al. Jan 2006 A1
20060052821 Abbot et al. Mar 2006 A1
20060074484 Huber Apr 2006 A1
20060178700 Quinn Aug 2006 A1
20060195134 Crittenden Aug 2006 A1
20060217762 Maahs et al. Sep 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060293698 Douk Dec 2006 A1
20070027533 Douk Feb 2007 A1
20070038292 Danielpour Feb 2007 A1
20070051377 Douk et al. Mar 2007 A1
20070055206 To et al. Mar 2007 A1
20070118151 Davidson May 2007 A1
20070142907 Moaddeb et al. Jun 2007 A1
20070185572 Solem et al. Aug 2007 A1
20070255396 Douk et al. Nov 2007 A1
20070293724 Saadat et al. Dec 2007 A1
20070293943 Quinn Dec 2007 A1
20080004696 Vesely Jan 2008 A1
20080004697 Lichtenstein et al. Jan 2008 A1
20080200980 Robin et al. Aug 2008 A1
20080208327 Rowe Aug 2008 A1
20080275503 Spence et al. Nov 2008 A1
20080275540 Wen Nov 2008 A1
20090030504 Weber Jan 2009 A1
20090088836 Bishop et al. Apr 2009 A1
20090093826 Warder-Gabaldon Apr 2009 A1
20090138079 Tuval et al. May 2009 A1
20090157174 Yoganathan et al. Jun 2009 A1
20090192601 Raffee et al. Jul 2009 A1
20090209950 Starksen Aug 2009 A1
20090222026 Rothstein et al. Sep 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090299471 Keranen Dec 2009 A1
20100010520 Takahashi et al. Jan 2010 A1
20100049239 McGuckin, Jr. et al. Feb 2010 A1
20100076497 Zwirkoski Mar 2010 A1
20100076549 Keidar Mar 2010 A1
20100094406 Leprince et al. Apr 2010 A1
20100185172 Fabro Jul 2010 A1
20100198056 Fabro et al. Aug 2010 A1
20100198192 Serina et al. Aug 2010 A1
20100198208 Napp et al. Aug 2010 A1
20100217385 Thompson et al. Aug 2010 A1
20100312333 Navia et al. Dec 2010 A1
20110022164 Quinn et al. Jan 2011 A1
20110040366 Goetz Feb 2011 A1
20110046600 Crank Feb 2011 A1
20110224785 Hacohen Sep 2011 A1
20110245911 Quill Oct 2011 A1
20110288637 De Nov 2011 A1
20110313515 Quadri et al. Dec 2011 A1
20110319989 Lane et al. Dec 2011 A1
20120022633 Olson Jan 2012 A1
20120053680 Bolling et al. Mar 2012 A1
20120143316 Seguin et al. Jun 2012 A1
20120197388 Khairkhahan et al. Aug 2012 A1
20120203333 McGuckin, Jr. et al. Aug 2012 A1
20120221101 Moaddeb et al. Aug 2012 A1
20120277734 Geotz et al. Nov 2012 A1
20120277853 Rothstein Nov 2012 A1
20130006352 Yaron Jan 2013 A1
20130023985 Khairkhahan et al. Jan 2013 A1
20130035758 Seguin et al. Feb 2013 A1
20130079873 Migliazza et al. Mar 2013 A1
20130116779 Weber May 2013 A1
20130123912 Tung et al. May 2013 A1
20130172992 Gross Jul 2013 A1
20130253643 Rolando et al. Sep 2013 A1
20130274873 Delaloye et al. Oct 2013 A1
20130325110 Khalil et al. Dec 2013 A1
20140005768 Thomas et al. Jan 2014 A1
20140031928 Murphy et al. Jan 2014 A1
20140081154 Toth May 2014 A1
20140200649 Essinger et al. Jul 2014 A1
20140228943 Stigall et al. Aug 2014 A1
20140249621 Eidenschink Sep 2014 A1
20140257467 Lane et al. Sep 2014 A1
20140277382 Dolan et al. Sep 2014 A1
20140277409 Börtlein et al. Sep 2014 A1
20140324163 Keränen et al. Oct 2014 A1
20140379074 Spence et al. Dec 2014 A1
20150005764 Hanson et al. Jan 2015 A1
20150018876 Ewers et al. Jan 2015 A1
20150039082 Keranen Feb 2015 A1
20150051709 Vasquez et al. Feb 2015 A1
20150134055 Spence et al. May 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150250480 Featherstone Sep 2015 A1
20150265403 Keränen Sep 2015 A1
20150272737 Dale et al. Oct 2015 A1
20150297346 Duffy et al. Oct 2015 A1
20150305863 Gray et al. Oct 2015 A1
20150327994 Morriss et al. Nov 2015 A1
20150328000 Ratz et al. Nov 2015 A1
20150335290 Hunter Nov 2015 A1
20150335426 Lim et al. Nov 2015 A1
20150351735 Keränen et al. Dec 2015 A1
20150351908 Keränen et al. Dec 2015 A1
20150351911 Keränen et al. Dec 2015 A1
20160089126 Guo Mar 2016 A1
20160095705 Keränen et al. Apr 2016 A1
20160113764 Sheahan et al. Apr 2016 A1
20160143689 Ditter May 2016 A1
20160143731 Backus et al. May 2016 A1
20160166380 Seguin et al. Jun 2016 A1
20160199177 Spence Jul 2016 A1
20160206853 Bolduc et al. Jul 2016 A1
20160228247 Maimon et al. Aug 2016 A1
20160235526 Lashinski et al. Aug 2016 A1
20160235529 Ma et al. Aug 2016 A1
20160242902 Morriss et al. Aug 2016 A1
20160242906 Morriss et al. Aug 2016 A1
20160324637 Hlavka et al. Nov 2016 A1
20160324639 Nguyen et al. Nov 2016 A1
20160331523 Chau et al. Nov 2016 A1
20160346080 Righini et al. Dec 2016 A1
20170056163 Tayeb et al. Mar 2017 A1
20170071732 Conklin et al. Mar 2017 A1
20170079790 Vidlund et al. Mar 2017 A1
20170112624 Patel Apr 2017 A1
20170119524 Salahieh et al. May 2017 A1
20170128203 Zhang et al. May 2017 A1
20170128204 Morriss et al. May 2017 A1
20170143481 Morriss et al. May 2017 A1
20170156723 Keating et al. Jun 2017 A1
20170165057 Morriss et al. Jun 2017 A9
20170189177 Schweich et al. Jul 2017 A1
20170216025 Nitzan et al. Aug 2017 A1
20170224479 Seguin Aug 2017 A1
20170245850 Call et al. Aug 2017 A1
20170258585 Marquez et al. Sep 2017 A1
20170273788 O'Carroll et al. Sep 2017 A1
20170273789 Yaron et al. Sep 2017 A1
20170281341 Lim et al. Oct 2017 A1
20170311937 Bambury et al. Nov 2017 A1
20170348099 Mendelson et al. Dec 2017 A1
20180021546 McDermott et al. Jan 2018 A1
20180049873 Manash et al. Feb 2018 A1
20180055628 Patel et al. Mar 2018 A1
20180092763 Dagan et al. Apr 2018 A1
20180110622 Gregg et al. Apr 2018 A1
20180116790 Ratz et al. May 2018 A1
20180133003 Levi May 2018 A1
20180153690 Spence Jun 2018 A1
20180177592 Benichou et al. Jun 2018 A1
20180177594 Patel Jun 2018 A1
20180206982 Haivatov et al. Jul 2018 A1
20180206986 Noe et al. Jul 2018 A1
20180206992 Brown Jul 2018 A1
20180207395 Bulman et al. Jul 2018 A1
20180214267 Lally et al. Aug 2018 A1
20180214270 Subramanian et al. Aug 2018 A1
20180221014 Darabian Aug 2018 A1
20180228608 Sheps et al. Aug 2018 A1
20180228610 Lashinski et al. Aug 2018 A1
20180235443 Smith et al. Aug 2018 A1
20180250126 O'Connor et al. Sep 2018 A1
20180250132 Ketai et al. Sep 2018 A1
20180263764 Manash et al. Sep 2018 A1
20180280171 Gloss et al. Oct 2018 A1
20180289473 Rajagopal et al. Oct 2018 A1
20180289474 Rajagopal et al. Oct 2018 A1
20180289478 Quill Oct 2018 A1
20180289480 D'Ambra et al. Oct 2018 A1
20180289485 Rajagopal et al. Oct 2018 A1
20180296335 Miyashiro Oct 2018 A1
20180296338 Rabito et al. Oct 2018 A1
20180318079 Patel et al. Nov 2018 A1
20180325665 Gurovich et al. Nov 2018 A1
20180333259 Dibie Nov 2018 A1
20180344303 Bambury et al. Dec 2018 A1
20180344454 Mauch et al. Dec 2018 A1
20180344459 Spence et al. Dec 2018 A1
20180344971 Suzuki et al. Dec 2018 A1
20180360600 Zhuang et al. Dec 2018 A1
20180368830 O'Carroll et al. Dec 2018 A1
20190000614 Morriss et al. Jan 2019 A1
20190000615 Tayeb et al. Jan 2019 A1
20190000625 O'Carroll et al. Jan 2019 A1
20190008635 Francis et al. Jan 2019 A1
20190008639 Landon et al. Jan 2019 A1
20190008640 Cooper et al. Jan 2019 A1
20190015205 Rajagopal et al. Jan 2019 A1
20190021859 O'Carrol et al. Jan 2019 A1
20190046315 Gao et al. Feb 2019 A1
20190053894 Levi et al. Feb 2019 A1
20190053895 Levi Feb 2019 A1
20190053898 Maimon et al. Feb 2019 A1
20190053899 Levi Feb 2019 A1
20190053903 Rohl et al. Feb 2019 A1
20190060068 Cope et al. Feb 2019 A1
20190060069 Maimon et al. Feb 2019 A1
20190060071 Lane et al. Feb 2019 A1
20190076244 Yohanan et al. Mar 2019 A1
20190076664 Ollivier Mar 2019 A1
20190117392 Quadri et al. Apr 2019 A1
20190133756 Zhang et al. May 2019 A1
20190133757 Zhang et al. May 2019 A1
20190142589 Basude May 2019 A1
20190159770 Rohl et al. May 2019 A1
20190160292 Peichel et al. May 2019 A1
20190167425 Reich et al. Jun 2019 A1
20190183649 Allen et al. Jun 2019 A1
20190192288 Levi et al. Jun 2019 A1
20190192294 Spence et al. Jun 2019 A1
20190192296 Schwartz et al. Jun 2019 A1
20190201191 McLean et al. Jul 2019 A1
20190209311 Zhang et al. Jul 2019 A1
20190209312 Zhang et al. Jul 2019 A1
20190209313 Zhang et al. Jul 2019 A1
20190209314 Zhang et al. Jul 2019 A1
20190209315 Zhang et al. Jul 2019 A1
20190209316 Zhang et al. Jul 2019 A1
20190209317 Zhang et al. Jul 2019 A1
20190209318 Zhang et al. Jul 2019 A1
20190209320 Drasler et al. Jul 2019 A1
20190231520 Desrosiers et al. Aug 2019 A1
20190240023 Spence et al. Aug 2019 A1
20190246916 Kuraguntla et al. Aug 2019 A1
20190254816 Anderson et al. Aug 2019 A1
20190261995 Goldfarb et al. Aug 2019 A1
20190261996 Goldfarb et al. Aug 2019 A1
20190261997 Goldfarb et al. Aug 2019 A1
20190262129 Cooper et al. Aug 2019 A1
20190282237 Goldfarb et al. Sep 2019 A1
20190328518 Neumann Oct 2019 A1
20190336282 Christianson et al. Nov 2019 A1
20190343625 Gharib et al. Nov 2019 A1
20190365530 Hoang et al. Dec 2019 A1
20190374337 Zamani et al. Dec 2019 A1
20190374342 Gregg et al. Dec 2019 A1
20200000579 Manash et al. Jan 2020 A1
20200000586 Tian et al. Jan 2020 A1
20200008936 Cheema et al. Jan 2020 A1
20200022811 Griswold et al. Jan 2020 A1
20200054453 Zerkowski et al. Feb 2020 A1
20200060813 Nguyen et al. Feb 2020 A1
20200060820 Ben-Zvi et al. Feb 2020 A1
20200078000 Rajagopal et al. Mar 2020 A1
20200093601 Neustadter Mar 2020 A1
20200107932 Rabito et al. Apr 2020 A1
20200107933 Oba Apr 2020 A1
20200113586 Karasic et al. Apr 2020 A1
20200113685 Miller et al. Apr 2020 A1
20200113696 Ekvall et al. Apr 2020 A1
20200138575 Tuval May 2020 A1
20200178977 Coleman et al. Jun 2020 A1
20200188107 Gloss et al. Jun 2020 A1
20200205800 Gilmore et al. Jul 2020 A1
20200205969 Hacohen Jul 2020 A1
20200205974 Zerkowski et al. Jul 2020 A1
20200205975 Khairkhahan Jul 2020 A1
20200205979 O'Carroll et al. Jul 2020 A1
20200214708 Sharma Jul 2020 A1
20200229806 Goldfarb et al. Jul 2020 A1
20200229918 Pham et al. Jul 2020 A1
20200275921 Gilmore et al. Sep 2020 A1
20200276017 Subramanian et al. Sep 2020 A1
20200297489 Bishop et al. Sep 2020 A1
20200352705 Heneghan et al. Nov 2020 A1
20200352706 Campbell Nov 2020 A1
20200360139 Hammer et al. Nov 2020 A1
20210022854 Zhao et al. Jan 2021 A1
20210022860 Lally et al. Jan 2021 A1
20210030536 Kaleta Feb 2021 A1
20210121289 Bruchman et al. Apr 2021 A1
20210128297 Braido et al. May 2021 A1
20210145573 Dasi et al. May 2021 A1
20210161688 Shahriari Jun 2021 A1
20210177583 Colavito et al. Jun 2021 A1
20210177584 Levi et al. Jun 2021 A1
20210177587 Braido Jun 2021 A1
20210228343 Scheinblum et al. Jul 2021 A1
20220054261 Argento et al. Feb 2022 A1
20230105492 Argento et al. Apr 2023 A1
20230118748 Argento Apr 2023 A1
20230165679 Boyd et al. Jun 2023 A1
20230225861 Argento et al. Jul 2023 A1
20240293217 Cartledge et al. Sep 2024 A1
Foreign Referenced Citations (115)
Number Date Country
2012261727 Oct 2015 AU
2019246822 Aug 2020 AU
2020227034 Sep 2020 AU
PI0820603 Jun 2020 BR
2979817 Sep 2016 CA
2954826 Oct 2019 CA
103764216 Apr 2014 CN
103974670 Aug 2014 CN
105358098 Feb 2016 CN
107690323 Feb 2018 CN
111110401 May 2020 CN
108601655 Jun 2020 CN
111265335 Jun 2020 CN
111278389 Jun 2020 CN
111329541 Jun 2020 CN
19857887 May 2005 DE
102014102650 Sep 2015 DE
1105181 Feb 2004 EP
1432369 Feb 2008 EP
2374415 Oct 2011 EP
2907479 Aug 2015 EP
3037064 Jun 2016 EP
3158975 Apr 2017 EP
3342355 Jul 2018 EP
3395296 Oct 2018 EP
3406225 Nov 2018 EP
3417831 Dec 2018 EP
3476366 May 2019 EP
3482718 May 2019 EP
2637607 Oct 2019 EP
3554424 Oct 2019 EP
3244809 Feb 2020 EP
3639792 Apr 2020 EP
3417831 May 2020 EP
3649963 May 2020 EP
2072027 Jun 2020 EP
3441045 Jul 2020 EP
3672528 Jul 2020 EP
3554423 Aug 2020 EP
3107498 Sep 2020 EP
3570782 Sep 2020 EP
3700467 Sep 2020 EP
3705090 Sep 2020 EP
3782585 Feb 2021 EP
H08131551 May 1996 JP
2004154177 Jun 2004 JP
2008018139 Jan 2008 JP
2011506017 Mar 2011 JP
2012531270 Dec 2012 JP
2020515375 May 2020 JP
2020517379 Jun 2020 JP
2020520729 Jul 2020 JP
6735294 Aug 2020 JP
2020032237 Mar 2020 KR
2020033349 Mar 2020 KR
2020033350 Mar 2020 KR
202027694 Aug 2020 TW
WO2007007873 Jan 2007 WO
WO2007081820 Jul 2007 WO
WO2010141847 Dec 2010 WO
WO2011025945 Mar 2011 WO
WO2012087842 Jun 2012 WO
WO2012145545 Oct 2012 WO
WO2013190910 Dec 2013 WO
WO2015127264 Aug 2015 WO
WO2015173609 Nov 2015 WO
WO2015195823 Dec 2015 WO
WO2016052145 Apr 2016 WO
WO2016117169 Jul 2016 WO
WO2016183485 Nov 2016 WO
WO2017121193 Jul 2017 WO
WO-2017151566 Sep 2017 WO
WO2017214098 Dec 2017 WO
WO2018025260 Feb 2018 WO
WO2018039561 Mar 2018 WO
WO2018039589 Mar 2018 WO
WO2018112429 Jun 2018 WO
WO2018119304 Jun 2018 WO
WO2018178966 Oct 2018 WO
WO2018178967 Oct 2018 WO
WO2018187390 Oct 2018 WO
WO2018192197 Oct 2018 WO
WO-2019010370 Jan 2019 WO
WO2019036592 Feb 2019 WO
WO2019062366 Apr 2019 WO
WO2019081777 May 2019 WO
WO2019102484 May 2019 WO
WO-2019086958 May 2019 WO
WO2019116369 Jun 2019 WO
WO-2019118371 Jun 2019 WO
WO2019135011 Jul 2019 WO
WO2019135028 Jul 2019 WO
WO2019144036 Jul 2019 WO
WO2019147504 Aug 2019 WO
WO2019147846 Aug 2019 WO
WO2019154124 Aug 2019 WO
WO2019164516 Aug 2019 WO
WO2019195860 Oct 2019 WO
WO2019209927 Oct 2019 WO
WO2019222694 Nov 2019 WO
WO2019241777 Dec 2019 WO
WO2020051147 Mar 2020 WO
WO2020051591 Mar 2020 WO
WO2020072199 Apr 2020 WO
WO2020072201 Apr 2020 WO
WO2020073050 Apr 2020 WO
WO2020082039 Apr 2020 WO
WO2020123719 Jun 2020 WO
WO2020157018 Aug 2020 WO
WO2020163112 Aug 2020 WO
WO2020210685 Oct 2020 WO
WO2020236830 Nov 2020 WO
WO2020247907 Dec 2020 WO
WO2021028867 Feb 2021 WO
WO2021034497 Feb 2021 WO
Non-Patent Literature Citations (31)
Entry
Westaby et al.; Adult human valve dimensions and their surgical significance; The American Journal of Cardiology; 53(4); pp. 552-556; Feb. 1984.
Argento et al.; U.S. Appl. No. 16/594,946 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Oct. 7, 2019.
Argento et al.; U.S. Appl. No. 16/723,537 entitled “Prothetic cardiac valve devices, systems, and methods,” filed Dec. 20, 2019.
Argento et al.; U.S. Appl. No. 16/824,576 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Mar. 19, 2020.
PCT/US2019/47842 International Search Report dated Jan. 2, 2020.
Argento et al.; U.S. Appl. No. 17/170,717 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Feb. 8, 2021.
Argento et al.; U.S. Appl. No. 17/286,724 entitled “Adjustable medical device,” filed Apr. 19, 2021.
Salahieh et al.; U.S. Appl. No. 17/543,555 entitled “Flared prosthetic cardiac valve delivery devices and systems,” filed Dec. 6, 2021.
Yang et al.; U.S. Appl. No. 17/651,040 entitled “Anchor for prosthetic cardiac valve delivery devices and systems”.
Salahieh.; U.S. Appl. No. 17/655,978 entitled “Anchor position verification for prosthetic cardiac valve devices,” filed Mar. 22, 2022.
Saul; U.S. Appl. No. 17/773,193 entitled “Prosthetic cardiac valve delivery devices, systems, and methods,” filed Apr. 29, 2022.
Argento et al.; U.S. Appl. No. 17/931,408 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Sep. 12, 2022.
Adamek-Bowers et al.; U.S. Appl. No. 18/043,458 entitled “Prosthetic valve delivery system,” filed Feb. 28, 2023.
Backus et al.; U.S. Appl. No. 18/004,609 entitled “Valve delivery system,” filed Jan. 6, 2023.
Mulcahy et al.; U.S. Appl. No. 18/043,480 entitled “Prosthetic cardiac valve delivery devices, systems, and methods,” filed Feb. 28, 2023.
Adamek-Bowers et al.; U.S. Appl. No. 18/043,499 entitled “Interface for prosthetic cardiac valve and delivery systems,” filed Feb. 28, 2023.
Salahieh et al.; U.S. Appl. No. 18/043,519 entitled “Flared prosthetic cardiac valve delivery devices and systems,” filed Feb. 28, 2023.
Scott et al.; U.S. Appl. No. 18/043,526 entitled “Access sheath for prosthetic cardiac valve delivery systems,” filed Feb. 28, 2023.
Yang et al.; U.S. Appl. No. 18/043,542 entitled “Anchor for prosthetic cardiac valve devices,” filed Feb. 28, 2023.
Argento et al.; U.S. Appl. No. 18/246,307 entitled “Systems, methods, and devices for expandable sensors,” filed Mar. 22, 2023.
Argento et al.; U.S. Appl. No. 18/246,311 entitled “Prosthetic cardiac valve sensor devices, systems, and methods with imaging,” filed Mar. 22, 2023.
Argento et al.; U.S. Appl. No. 18/185,330 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Mar. 16, 2023.
Adamek-Bowers et al.; U.S. Appl. No. 18/255,763 entitled “Mitral valve implants,” filed Jun. 2, 2023.
Schaefer; Large heart valves—small heart valves; ISMAAP; Oct. 19, 2015; 5 pages; retrieved from the internet (https://www.ismaap.org/condition-detail/large-heart-valves-small-heart-valves/) on Mar. 21, 2023.
Argento et al.; U.S. Appl. No. 18/494,520 entitled “Prosthetic cardiac valve devices, systems, and methods,” filed Oct. 25, 2023.
Mulcahy et al.; U.S. Appl. No. 18/573,816 entitled “Prosthetic cardiac valve delivery devices, systems, and methods,” filed Dec. 22, 2023.
Boyd et al.; U.S. Appl. No. 18/688,735 entitled “Guide catheter for prosthetic cardiac valve delivery systems, ” filed Mar. 1, 2024.
Adamek-Bowers et al.; U.S. Appl. No. 18/693,856 entitled “Tether delivery of cardiac valve,” filed Mar. 20, 2024.
Yang et al.; U.S. Appl. No. 18/700,621 entitled “Cardiac valve prosthesis delivery system and methods of use,” filed Apr. 11, 2024.
Argento et al.; U.S. Appl. No. 18/639,743 entitled “Prosthetic cardiac valve devices, systems and methods,” filed Apr. 18, 2024.
Masterclass; Knit vs. Woven: Learn How to Identify the Two Fabric Types; Jun. 7, 2021; 13 pages; retrieved from the internet (https://www.masterclass.com/articles/knit-vs-woven-learn-how-to-identify-the-two-fabric-types) on Nov. 15, 2024.
Related Publications (1)
Number Date Country
20200060852 A1 Feb 2020 US
Provisional Applications (1)
Number Date Country
62720853 Aug 2018 US